#1 Clinical Trials Search in Europe

CANNABINOL

Cannabinol (CBN) is a naturally occurring cannabinoid found in the cannabis plant that is being studied for its potential therapeutic properties. Unlike more well-known cannabinoids such as THC (tetrahydrocannabinol) and CBD (cannabidiol), CBN has received less attention in research until recently. Current clinical trials are exploring CBN’s effectiveness in treating various conditions including insomnia, pain management, skin disorders, and other medical applications. This article examines the current landscape of clinical trials investigating cannabinol’s potential benefits, safety profile, and effectiveness across different medical conditions.

Table of Contents

What is Cannabinol (CBN)?

Cannabinol (CBN) is a type of cannabinoid compound found in the cannabis plant. Unlike more well-known cannabinoids such as THC (tetrahydrocannabinol) and CBD (cannabidiol), CBN has been less studied but is gaining attention for its potential therapeutic benefits[1]. CBN is actually a breakdown product that forms when THC ages and oxidizes.

CBN is being researched for several potential medical applications, including:

  • Treatment of insomnia and sleep disorders
  • Pain management
  • Treatment of skin conditions, particularly epidermolysis bullosa

CBN can be administered in various forms depending on the condition being treated, including oral capsules, topical creams, and liquid formulations suspended in medium chain triglycerides (MCT) oil[1][2].

CBN for Insomnia Disorder

One of the most promising areas of research for CBN is in the treatment of insomnia disorder. Insomnia is characterized by difficulty falling asleep, staying asleep, or getting restorative sleep, which can significantly impact daily functioning and quality of life[1].

Clinical research is currently investigating how CBN might affect sleep architecture and next-day functioning in adults with chronic insomnia. In a randomized, double-blind, placebo-controlled study, researchers are examining two different doses of CBN (30 mg and 300 mg) to determine their effects on:

  • Wake After Sleep Onset (WASO) – the amount of time spent awake after initially falling asleep
  • Sleep Onset Latency (SOL) – how long it takes to fall asleep
  • Proportions of different sleep stages (wake, N1, N2, N3, and REM sleep)
  • Brain activity during sleep as measured by electroencephalography (EEG)
  • Next-day functioning and alertness

The study measures these effects using polysomnography (a comprehensive sleep study that records brain waves, oxygen levels, heart rate, and breathing) and various subjective assessments[1].

CBN for Epidermolysis Bullosa

Epidermolysis bullosa (EB) is a group of rare genetic skin disorders characterized by extremely fragile skin that blisters and tears easily. People with EB experience painful wounds and blisters that can significantly impact their quality of life[2].

Research is investigating the potential of CBN as a topical treatment for EB through a cream called INM-755. This randomized, double-blind, vehicle-controlled study aims to evaluate both the safety and preliminary efficacy of CBN cream in treating:

  • Wound healing – measured by changes in wound surface area
  • Wound pain – both procedural pain (during dressing changes) and background pain
  • Itch (pruritus) – both in wound areas and non-wound areas

The study includes patients with different types of EB (Simplex, Dystrophic, Junctional, or Kindler) and uses a within-patient design where matched areas of skin are treated with either CBN cream or a placebo cream for comparison[2].

The research is particularly important because current treatment options for EB are limited, and this condition causes significant pain and discomfort for patients.

CBN for Pain Management After Surgery

Another area of investigation for CBN is post-surgical pain management, particularly after procedures like total knee replacement surgery. This type of orthopedic surgery can result in significant pain, which is traditionally managed with opioid medications[3].

While opioids are effective for pain control, they come with significant side effects and risks, including:

  • Confusion
  • Nausea and vomiting
  • Constipation
  • Risk of addiction and dependence

Research is exploring whether CBN can help reduce the amount of opioid medication needed after surgery, potentially decreasing these unwanted side effects. The COPE (Cannabinoids to Obviate Pain Experiment) study is investigating whether adding CBN to standard pain management can decrease total opioid consumption in the first two weeks after knee replacement surgery[3].

Measurements in this study include:

  • Total opioid consumption (measured as morphine equivalent doses)
  • Pain levels using visual analog scales
  • Quality of recovery and function
  • Long-term opioid use

CBN Compared to Other Cannabinoids

CBN is just one of many cannabinoids found in or derived from the cannabis plant. It differs from more well-known cannabinoids like THC and CBD in several important ways[4][5]:

  • THC (Tetrahydrocannabinol): The primary psychoactive component of cannabis that causes the “high” sensation. THC has been studied for effects on orientation, motor coordination, and brain metabolism, as well as for reducing postoperative nausea and vomiting.
  • CBD (Cannabidiol): A non-psychoactive cannabinoid that has gained popularity for potential anti-inflammatory, anxiolytic, and pain-relieving properties.
  • CBN (Cannabinol): Forms when THC ages and oxidizes. Early research suggests it may have sedative properties and potential benefits for sleep, pain, and skin conditions without the strong psychoactive effects of THC.

Unlike THC, CBN is not thought to produce strong psychoactive effects, making it potentially more suitable for medical use in situations where impairment would be problematic[1].

Safety Profile and Side Effects

Research into CBN’s safety profile is still ongoing, but current studies are investigating potential side effects and risks. Some of the safety outcomes being monitored in clinical trials include[1]:

  • Effects on driving ability and coordination
  • Impact on mood and subjective drug effects
  • Postural stability
  • Alertness and reaction time
  • Memory and cognitive function

Researchers are also measuring how CBN is processed by the body by analyzing cannabinoid concentrations in plasma, urine, and saliva samples[1].

For topical applications like the CBN cream being tested for epidermolysis bullosa, researchers are primarily concerned with local skin reactions and safety at the application site[2].

Current Research Status

It’s important to note that research on CBN is still in relatively early stages compared to other cannabinoids like THC and CBD. Most of the studies described are Phase 2 clinical trials, which means they are designed to gather preliminary data on effectiveness and further evaluate safety[1][2][3].

Key points about the current research status:

  • CBN for insomnia is being studied in a pilot trial with 20 participants to determine its effects on sleep architecture and next-day function[1].
  • The INM-755 CBN cream for epidermolysis bullosa is being evaluated in a randomized trial to assess safety and obtain preliminary evidence of efficacy[2].
  • Research on CBN for post-surgical pain management is investigating whether it can reduce opioid consumption after knee replacement surgery[3].

While these studies show promising directions for CBN research, larger and more comprehensive clinical trials will be needed before definitive conclusions can be drawn about efficacy and safety for various conditions.

Condition Study Design CBN Formulation Dosage Key Outcomes Measured
Insomnia Disorder Randomized, double-blind, placebo-controlled, crossover Oral liquid CBN (ECS 310) 30mg and 300mg Wake After Sleep Onset (WASO), sleep stages, sleep onset latency, EEG patterns, next-day function
Epidermolysis Bullosa Randomized, double-blind, vehicle-controlled INM-755 topical cream Applied daily to non-wound areas, every 1-3 days on wounds Wound healing, wound surface area, pain (procedural and background), itch intensity
Post-Knee Replacement Pain Randomized, placebo-controlled, superiority trial Oral capsules Not specified Opioid consumption, pain scores, quality of recovery, patient-reported outcomes
Orientation/Coordination in Regular Cannabis Users Comparative study Smoked in cigarettes 13mg and 17mg Brain metabolic activity, reaction time, performance errors
Postoperative Nausea and Vomiting Controlled trial Intravenous 0.125mg/kg Absence of nausea/vomiting, psychological and physiological effects

Ongoing Clinical Trials on CANNABINOL

  • Cannabidiol for Alcohol Dependence in Adults Seeking Abstinence: A Phase II Placebo‑Controlled Trial

    Not yet recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study of Cannabidiol compared to placebo to treat alcohol dependence in adults seeking treatment to achieve abstinence

    Not yet recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Cannabidiol for Treating Alcohol Dependence in Patients Seeking Abstinence

    Not yet recruiting

    2 1
    Investigated diseases:
    Investigated drugs:
    Spain

Glossary

  • Cannabinol (CBN): A naturally occurring cannabinoid found in the cannabis plant that forms when THC ages. Unlike THC, it is not significantly psychoactive at typical therapeutic doses. Being studied for potential benefits in sleep disorders, pain management, and skin conditions.
  • Insomnia Disorder: A sleep disorder characterized by difficulty falling asleep, staying asleep, or both, leading to inadequate or poor-quality sleep that affects daytime functioning. In clinical trials, it's diagnosed using criteria including an Insomnia Severity Index (ISI) Score ≥15.
  • Epidermolysis Bullosa (EB): A group of rare genetic skin disorders characterized by extremely fragile skin that blisters and tears easily. There are several types including Simplex, Dystrophic, Junctional, and Kindler Syndrome, all being studied in CBN clinical trials.
  • Polysomnography (PSG): A comprehensive recording of biophysiological changes during sleep. In CBN trials, it's used to measure sleep architecture, brain activity, eye movements, muscle activity, and heart rhythm to evaluate sleep quality objectively.
  • Wake After Sleep Onset (WASO): A measurement of the amount of time spent awake after initially falling asleep. In sleep studies, it's an important indicator of sleep quality and continuity, measured in minutes using polysomnography.
  • Sleep Architecture: The structure of sleep, including the various sleep stages (N1, N2, N3, and REM sleep) and their patterns throughout the night. CBN trials measure how the substance affects these sleep stages.
  • Electroencephalography (EEG): A method to record electrical activity of the brain. In CBN trials, it's used to measure brain activity during sleep and wakefulness to evaluate effects on sleep stages and alertness.
  • Sleep Spindles: Bursts of neural activity that appear on an EEG during stage 2 sleep. These are being measured in CBN trials to understand effects on sleep quality and memory consolidation.
  • Vehicle Cream: In clinical trials, a cream that contains the same base ingredients as the active treatment but without the active ingredient (in this case, without CBN). Used as a control to compare against the active treatment.
  • Double-blind Study: A research design where neither the participants nor the researchers know who is receiving the experimental treatment versus placebo, reducing bias in observed outcomes.
  • Crossover Design: A clinical trial design where participants receive different treatments in sequence, allowing each person to serve as their own control. In CBN studies, participants may receive both CBN and placebo in different periods.
  • Randomized Controlled Trial: A study design where participants are randomly assigned to either a treatment or control group, allowing researchers to compare outcomes between groups.
  • Visual Analog Scale (VAS): A measurement tool used to assess subjective characteristics or attitudes that cannot be directly measured. In CBN trials, it's used to measure pain and itch intensity on a scale from 0 to 100mm.
  • Medium Chain Triglycerides (MCT) Oil: A type of fat that is more easily digested than longer-chain fatty acids. In CBN trials, it's used as a carrier oil for the cannabinoid formulations.
  • Placebo: An inactive substance that looks identical to the drug being tested. In CBN trials, placebos are used to control for psychological effects of treatment and establish true efficacy.

References

  1. https://clinicaltrials.gov/study/NCT05344170
  2. https://clinicaltrials.gov/study/NCT04908215
  3. https://clinicaltrials.gov/study/NCT03675971
  4. https://clinicaltrials.gov/study/NCT00270803
  5. https://clinicaltrials.gov/study/NCT00695487